SAN DIEGO, Dec. 1 TargeGen has announced that an oralpresentation of preliminary results from a multi-center, US-based clinicaltrial of TG101348 in myeloproliferative disease patients has been scheduled atthe 2008 American Society of Hematology (ASH) Meeting.
About TargeGen, Inc.
TargeGen, Inc. is a privately held vascular biology-focusedbiopharmaceutical company based in San Diego, CA. TargeGen primarily developssmall molecule kinase inhibitors that target vascular leakage (edema),vascular proliferation (angiogenesis) and inflammation. Edema, angiogenesisand inflammation are involved in the pathology of many major human diseases.TargeGen initiated operations in 2002 and has raised capital from top tierventure capital sources. Current investors include VantagePoint VenturePartners, Forward Ventures, Enterprise Partners, Chicago Growth Partners, BBBIOTECH VENTURES, Innovis Investments, H&Q Capital Management, PappasVentures, CTI Life Sciences and other investors.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)Details of the presentation are as follows: Title: A Phase I Study of TG101348, an Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis Presenter: Dr. Animesh Pardanani, Mayo Clinic Session Name: Myeloproliferative Disorders-Experimental Therapeutics Session Date: Sunday, December 7, 2008 Presentation Time: 4:30 PM Room: Moscone Center SOUTH, Rooms 304-306-308 Directions: Howard Street entrance, turn left, up 2 flights of stairs to Esplanade level
SOURCE TargeGen, Inc.